Print
Email
Print Edition StoriesWednesday, August 5, 2009
Genzyme’s blood cancer treatment lands European approval
By Mass High Tech staff
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: RI plans launch of cord blood center
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Cambridge biotechnology giant Genzyme Corp. has been granted approval from the European Commission to market its Mozobil treatment of blood cancers. The treatment is expected to provide a new option for patients with lymphoma and multiple myeloma in need of an autologous stem cell transplant.
Currently in orphan drug status in both the U.S. and the European Union, Mozobil is designed to work in combination with granulocyte-colony stimulating factor (G-CSF) to improve stem cell collection for transplantation in those patients with blood cancers who may have poor cell mobilization. The process of collecting enough stem cells for transplant can take several hours over several days, according to the company.
Genzyme officials noted in a statement that the treatment can reduce costs for transplant centers by improving efficiency and predicted outcomes, as well as reduce the number of patients who require a second mobilization procedure.
Genzyme (Nasdaq: GENZ) launched Mozobil in Mexico in April, and it is currently seeking marketing approval in Argentina, Australia, Brazil, Israel and Singapore.
Founded in 1981, Genzyme is a global biotech firm focused on rare inherited disorders, kidney disease, cancer, transplant and immune disease and diagnostic testing.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
